Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation.
CONCLUSIONS: Baseline characteristics, rather than oral anticoagulation prescription at discharge, were associated with adverse outcomes following successful transcatheter aortic valve implantation. Conversely, oral anticoagulation was associated with reduced valvular haemodynamic deterioration. PMID: 32115397 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - February 26, 2020 Category: Cardiology Authors: Guedeney P, Huchet F, Manigold T, Overtchouk P, Rouanet S, Balagny P, Leprince P, Lebreton G, Letocart V, Barthelemy O, Vicaut E, Montalescot G, Guerin P, Collet JP, ACTION Study Group Tags: Arch Cardiovasc Dis Source Type: research

Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study
ConclusionMMACS patients with insufficient DAPT management experienced relatively more ischemic events. DAPT for at least 1  year may be beneficial to this special population without significantly increasing the bleeding risks.Trial registrationClinicalTrials.gov identifier, NCT01735305.
Source: Advances in Therapy - May 15, 2020 Category: Drugs & Pharmacology Source Type: research

Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI.
Authors: Wang HY, Gao RL, Xu B, Yang YJ, Yin D, Wang Y, Dou KF Abstract The benefits and harms of dual antiplatelet therapy (DAPT) continuation with aspirin and clopidogrel beyond 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for high ischemic or bleeding risk patients remain unclear. All consecutive patients undergoing PCI were prospectively included in the Fuwai PCI Registry from January 2013 to December 2013. We evaluated 7521 patients who were at high risk for thrombotic or hemorrhagic complications and were events free at 1 year after the index procedure. "TWI...
Source: Platelets - June 7, 2020 Category: Hematology Tags: Platelets Source Type: research

Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care*
Conclusions: Concomitant aspirin and anticoagulation in critically ill surgical patients was associated with an increased rate of major bleeding. Future investigations are warranted to further define optimal management of antiplatelet therapy during anticoagulation in surgical patients.
Source: Critical Care Medicine - June 20, 2020 Category: Emergency Medicine Tags: Clinical Investigations Source Type: research

Benefit-Risk Profile of DAPT Continuation Beyond 1  Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline
ConclusionsAmong patients with ESC-endorsed HTR who were free from major ischemic or bleeding events 1  year after coronary stenting, continued DAPT beyond 1 year might offer better effectiveness in terms of atherothrombotic events and comparable safety in terms of clinically relevant bleeding compared with ≤ 1-year DAPT. ESC-HTR criteria is an important parameter to take into account in tailor ing DAPT prolongation.
Source: Cardiovascular Drugs and Therapy - June 28, 2020 Category: Cardiology Source Type: research

P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
ConclusionsThis meta-analysis showed a significantly lowered risk of major bleeding and similar benefits of P2Y12 inhibitor monotherapy after short-term DAPT compared with standard-term DAPT in patients undergoing PCI.
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research

Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial.
CONCLUSION: In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor is associated with maintained anti-ischemic efficacy while protecting these patients against the excess risk for bleeding. PRIMARY FUNDING SOURCE: German Center for Cardiovascular Research and Deutsches Herzzentrum München. PMID: 32687741 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 20, 2020 Category: Internal Medicine Authors: Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, Richardt G, Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Lahu S, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Schüpke S, Kastrati A Tags: Ann Intern Med Source Type: research

A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial.
CONCLUSIONS: The TALOS-AMI trial is the first large-scale, multicenter, randomized study exploring the efficacy and safety of the de-escalating antiplatelet therapy that switches ticagrelor to clopidogrel in stabilized AMI patients undergoing PCI. PMID: 32718912 [PubMed - as supplied by publisher]
Source: EuroIntervention - July 30, 2020 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials
ConclusionIn patients with ACS undergoing PCI, both prasugrel and ticagrelor were associated with similar cardiovascular outcomes and adverse bleeding events.
Source: Cardiovascular Drugs and Therapy - August 19, 2020 Category: Cardiology Source Type: research

Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry
ConclusionsIn HF outpatients, antithrombotics are widely used. Bleeding occurs at a stable rate of 1.2% annually (as frequent as ischaemic events) and is associated with a dramatic increase in mortality (at least as severe as ischaemic events). Most events occurred in patients receiving anticoagulation. Knowledge of these findings may help physicians to manage antithrombotics in HF patients.
Source: ESC Heart Failure - September 10, 2020 Category: Cardiology Authors: Gilles Lemesle, Sandro Ninni, Pascal Groote, Guillaume Schurtz, Nicolas Lamblin, Christophe Bauters Tags: Original Research Article Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention 　- From the CREDO-Kyoto Registry Cohort-3.
CONCLUSIONS: The J-HBR criteria successfully identified those patients with very high bleeding risk after PCI, who represented 64% of patients in this all-comers registry. PMID: 33298644 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 8, 2020 Category: Cardiology Authors: Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, Tada T, Suwa S, Kaneda K, Watanabe H, Tazaki J, Watanabe S, Yamamoto E, Saito N, Fuki M, Takeda T, Eizawa H, Shinoda E, Mabuchi H, Shirotani M, Uegaito T, Matsuda M, Takahashi M, Inoko M, T Tags: Circ J Source Type: research

ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
Conclusion ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. ClinicalTrials.gov Identifier NCT04271293
Source: Journal of Cardiovascular Medicine - February 4, 2021 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

TAVR in nonagenarians: An analysis investigating safety, efficacy, symptomatic improvement, and long-term survival.
CONCLUSIONS: Out of 2336 patients, 2183 were younger than 90 years (<90y.-group) and 153 patients were aged 90 or older (≥90y.-group). Procedure-related mortality (3.6% <90y.-group vs. 3.3% ≥90y.-group, log-rank p=0.9) and device success (97.2% <90y.-group vs. 96.0% ≥90y.-group, p=0.44) were similar. Estimated survival rates at 2 years were 62.8% (95% CI 55.3 and 71.4) in the elder and 76.0% (95% CI 74.1 and 77.8) in the younger patients (p<0.01). The incidence of acute kidney injury, stroke, major bleeding, and permanent pacemaker implantations were comparable between both groups. TAVR procedure is equal...
Source: Journal of Cardiology - February 6, 2021 Category: Cardiology Authors: Zadrozny M, Hainzer N, Mehilli J, Jochheim D, Gschwendtner S, Steffen J, Theiss H, Braun D, Hagl C, Sadoni S, Massberg S, Hausleiter J, Deseive S Tags: J Cardiol Source Type: research

Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients
In conclusion, poor metabolizers of CYP2C19 and TT groups of P2Y12 G52T may be significant predictors of poor clinical outcomes in elderly patients.PMID:33707344 | DOI:10.18632/aging.202799
Source: Aging - March 12, 2021 Category: Biomedical Science Authors: Jung-Joon Cha Jae Hyoung Park Hyung Joon Joo Soon Jun Hong Tae Hoon Ahn Byeong-Keuk Kim WonYong Shin Sung Gyun Ahn JungHan Yoon Yong Hoon Kim Yun-Hyeong Cho Woong Chol Kang Weon Kim Young-Hyo Lim Hyeon Cheol Gwon Woong Gil Choi Do-Sun Lim Source Type: research